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Abstract
Objective: To determine the capacity of dendritic cells (DCs) loaded with single or multiple-peptide mixtures of novel
hepatitis C virus (HCV) epitopes to stimulate HCV-specific cytotoxic T lymphocyte (CTL) effector functions.
Methods: A bioinformatics approach was used to predict HLA-A2-restricted HCV-specific CTL epitopes, and the predicted
peptides identified from this screen were synthesized. Subsequent IFN-c ELISPOT analysis detected the stimulating function
of these peptides in peripheral blood mononuclear cells (PBMCs) from both chronic and self-limited HCV infected subjects
(subjects exhibiting spontaneous HCV clearance). Mature DCs, derived in vitro from CD14
+ monocytes harvested from the
study subjects by incubation with appropriate cytokine cocktails, were loaded with novel peptide or epitope peptide
mixtures and co-cultured with autologous T lymphocytes. Granzyme B (GrB) and IFN-c ELISPOT analysis was used to test for
epitope-specific CTL responses. T-cell-derived cytokines contained in the co-cultured supernatant were detected by flow
cytometry.
Results: We identified 7 novel HLA-A2-restricted HCV-specific CTL epitopes that increased the frequency of IFN-c-producing
T cells compared to other epitopes, as assayed by measuring spot forming cells (SFCs). Two epitopes had the strongest
stimulating capability in the self-limited subjects, one found in the E2 and one in the NS2 region of HCV; five epitopes had a
strong stimulating capacity in both chronic and self-limited HCV infection, but were stronger in the self-limited subjects.
They were distributed in E2, NS2, NS3, NS4, and NS5 regions of HCV, respectively. We also found that mDCs loaded with
novel peptide mixtures could significantly increase GrB and IFN-c SFCs as compared to single peptides, especially in chronic
HCV infection subjects. Additionally, we found that DCs pulsed with multiple epitope peptide mixtures induced a Th1-
biased immune response.
Conclusions: Seven novel and strongly stimulating HLA-A2-restricted HCV-specific CTL epitopes were identified.
Furthermore, DCs loaded with multiple-epitope peptide mixtures induced epitope-specific CTLs responses.
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Introduction
Chronic hepatitis C virus (HCV) infection is a serious health
problem worldwide. There are estimated to be more than 170
million carriers of hepatitis C infection. Approximately 3 or 4
million new cases arise every year [1,2]. Moreover, chronic HCV
infection is a potential cause of end-liver disease, such as liver
cirrhosis, hepatocellular carcinoma, and hepatic failure [3].
Currently, the standard therapy is a combination therapy of
pegylated interferon (Peg-interferon) and ribavirin. However, the
treatment efficiency of this therapy is variable depending on the
HCV genotype; it is approximately 50% effective in treating HCV
genotypes 1 and 4 and approximately 80% effective in treating
HCV genotypes 2 and 3. In addition, combination therapy has
severe adverse side effects as well as a high cost [4,5]. Moreover,
the high mutation rate of HCV and lack of effective animal models
have restricted the development of preventive and therapeutic
vaccines [6]. Therefore, exploration of new therapeutic strategies
is urgently needed.
The cellular immune response in both the innate and adaptive
immune responses is significantly impaired during chronic HCV
infection. Dendritic cells (DCs) are professional antigen presenta-
tion cells (APCs) that play a crucial role in innate immunity and in
priming T lymphocytes for the adaptive immune response.
However, previous studies have shown that DC function is
impaired in persistent HCV infection, which results in ineffective
T cell priming [7–10]. Consistent with this, previous reports have
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epitope CD8
+ or CD4
+ T lymphocyte response in self-limited
HCV infection, there is a narrow and weak T cell response in
persistent HCV infection [11,12]. In addition, other studies found
that T cells from chronic HCV infected subjects exhibited high
levels of PD-1 or Tim3 [13,14]; these surface markers correlated
with an anergic or exhausted state.
Because T cells play a vital role in determining whether
HCV infection persists or is eliminated from the host, one
promising strategy is to induce or enhance the T lymphocyte
response. A numbers of studies have shown that peptide-specific
cytotoxic T lymphocytes (CTLs) could be induced using
recombinant DNA or a protein vaccine in vitro; some of these
strategies were even developed into clinical trials to treat
chronic HCV subjects [15–17]. However, the antiviral effect of
these induced peptide-specific CTLs is limited. Another
developed therapeutic strategy is to use DCs loaded with
corresponding antigen in tumor subjects that can induce a
peptide-specific CTL response [18–20]. Last year, the DC
vaccine PROVENG was approved by the FDA to treat prostate
cancer [21]. DC immunotherapy has even been used to treat
HCV-infected individuals in a phase I clinical trial, where DCs
were loaded with lipopeptide; this treatment was determined to
be safe and was well tolerated [22]. Based on this encouraging
clinical result, DC-based immunotherapy to treat chronic
hepatitis C is expected to be an emerging field of research
[23,24].
In this study, we used bioinformatics to predict HLA-A2-
restricted HCV-specific CTL epitope peptides and subsequently
evaluated their potential to stimulate PBMCs using IFN-c
ELISPOT as a readout. We then tested the T-lymphocyte
stimulating capacity of DCs pulsed with selected immunodomi-
nant single peptides or multiple-epitope peptide mixtures to
determine whether this would be an efficient strategy to induce a
more effective T cell response against HCV that would eventually
clear persistent infection. We found that these novel peptides could
induce a Th1-biased T cell immune response, suggesting that these
peptides could improve the frequency of effective anti-HCV T
cells that could eventually eliminate the HCV infection from
chronically infected hosts.
Materials and Methods
Study Subjects
The study population consisted of 6 HLA-A2-positive chronic
hepatitis C (CHC) infected subjects and 5 HLA-A2–positive HCV
subjects that demonstrated spontaneous HCV clearance (hereafter
called self-limited). We categorized CHC subjects as being positive
for anti-HCV Abs as well as being HCV RNA positive, while self-
limited HCV subjects were positive for anti-HCV Abs but were
HCV RNA negative. The subjects were infected with hepatitis C
by apheresis plasma reinfusion in the 1990s. CHC subjects were
not treated during the six months before this study. Study subjects
also positive for other conditions, including HBV, HIV, autoim-
mune hepatitis, and serious heart or lung disease, were excluded
from the study. The detailed characteristics are listed in Table 1.
Written informed consent was obtained from all subjects. The
protocol of the study was approved by the ethics committee of
Peking University People’s Hospital.
Epitope Peptides Prediction and Synthesis
For peptide prediction, we chose an HCV prototype (genotype
1b) isolated in China from Genbank (L02836.1) [25]. The online
program CTLPred was used to predict HCV-specific CD8
+ T-
lymphocyte epitopes [26]. The criteria for identifying candidate
epitope peptide were as follows: (1) HLA-A2 restricted; (2)
relatively conserved in HCV genotypes 1 and 2; (3) high epitope
score compared to the threshold (Cut off=0.36, which has a high
sensitivity, specificity, precision and accuracy); (4) unique sequence
has not been previously reported. Moreover, we applied text
mining by using keywords in Pubmed and selected several HLA-
A2-restricted hepatitis C-specific CTL epitopes, which were
reported to have a stronger stimulating capability of IFN-c. And
we want to know whether these epitope peptide had the same
stimulatory function in the Chinese.
The 9-mer peptides were synthesized using an automated
multiple-peptide synthesizer (Invitrogen, Shanghai, China) and the
purity was assessed to be .98% through high-performance liquid
chromatography (HPLC) testing. The molecular mass is consistent
with the predicted value by mass spectrography analysis. All
peptides were solved in DMSO (Sigma, Shanghai, China), diluted
in sterile PBS, and stored at 280uC for subsequent use.
Screening and Identifying Epitope Peptides by IFN-c
ELISPOT
IFN-c ELISPOT (BD Pharmingen, San Diego, CA, USA)
was used to functionally screen epitope peptides. The protocol
used in this study was previously described [27,28] and
manufacturer’s recommended protocol was followed. Briefly,
polyvinylidene plates (96-well, Millipore, Billerica, MA, USA)
were coated with 2.5 mg/mL recombinant anti-human IFN-c
Abs (BD, Pharmingen) in PBS at 4uC overnight and washed
one time with complete RPMI (cRPMI) 1640 medium (Gibco/
Invitrogen, Carlsbad, CA, USA) containing 10% FBS (Gibco/
invitrogen, Mulgrave Vic, Australia). After blocking with cRPMI
1640 for 2 h at room temperature, fresh or previously frozen
PBMCs were added at 2610
5 cells/well in 100 mL of cRPMI
1640 media. Then, the synthesized peptides were directly added
to the well at a final concentration of 10 mg/mL. The plates
were incubated for 20 h at 37uCi n5 %C O 2. The cells were
removed and the plates were washed 2 times with distilled water
and subsequently washed 3 times with PBS containing 0.05%
Tween-20 (PBS-T) (Sigma, Shanghai, China). The plates were
developed with biotin-labeled anti-IFN-c for 2 h at room
temperature and then washed 3 times with PBS-T. The plates
were then incubated with streptavidin-HRP for 1 h at room
temperature, washed 4 times with PBS-T, and washed 3 times
by PBS. To develop the plate, 3-Amino-9-ethylcarbazole (AEC)
substrate (BD Pharmingen, San Diego, CA, USA) was added,
and the color was allowed to develop for approximately 10 min.
The reaction was stopped by distilled water and dried by air at
room temperature. The spots were counted using an ELISPOT
reader (Cellular Technology Ltd, USA) and analyzed by the
Immunospot 5.0.3 Professional (Cellular Technology Ltd, USA)
software. Each epitope was run in triplicate and the data was
expressed as the number of spot-forming cells (SFCs) per 2610
5
PBMCs. Phytohemagglutinin (PHA, Sigma, Shanghai, China)
served as a positive control for T cell stimulation. An HLA-A2–
restricted CTL epitope (WLSLLVPFV) from an envelope
protein from the hepatitis B virus (HBV) was selected as an
unrelated epitope peptide control. PBMCs cultured in medium
without any peptides were used as a negative control. If the
SFC per tested well at least 25 SFCs/2610
5 PBMCs after the
SFC value of the negative control was subtracted from the raw
number and the stimulatory function in self-limited HCV
infection was stronger than in the chronic infection, the
response was considered positive.
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PBMCs from chronic HCV infection and self-limited HCV
infection subjects were isolated by density gradient centrifuga-
tion using Ficoll-Paque Plus (GE Health Bio-science, AB,
Sweden) as described [29]. Untouched monocytes from fresh
or cryopreserved PBMCs were separated by negative selection
by the monocyte isolation Kit II (Miltenyi Biotec, Bergisch
Gladbach, Germany). The magnetically labeled monocyte-
depleted cells were frozen in liquid nitrogen as the source of
autologous T lymphocytes. The purity of CD14
+ monocytes by
flow cytometry was .90% and the viability of monocytes was
.95% by trypan blue staining.
The DC generation procedure was followed as previously
described by Romani et al. and Kim et al. [30,31] with slight
modifications. Briefly, monocytes (2610
6/well) were incubated
for 5 days in AIM V medium (Gibco/Invitrogen, Carlsbad, CA)
containing 800 U/mL of animal-free (AF) recombinant inter-
leukin 4 (rhIL-4) (Peprotech, Rocky Hill, NJ, USA) and
1000 U/mL AF-recombinant granulocyte-monocyte colony-
stimulating factor (rhGM-CSF) (Peprotech, Rocky Hill, NJ,
USA) to induce immature DC (iDC). Fresh medium containing
these cytokines was replaced every 3 days. On day 5, to induce
mature DCs (mDCs), iDCs were exposed to a cytokine cocktail
containing AF-recombinant IL-1b (1000 U/mL) (Peprotech,
Rocky Hill, NJ, USA), IL-6 (1000 U/mL) (Peprotech, Rocky
Hill, NJ, USA) and TNF-a (1000 U/mL) (Peprotech, Rocky
Hill, NJ, USA). After 6 h, a 10 mg/mL final concentration of
PolyI:C (Invivogen, San Diego, CA, USA) was added to iDCs
and cultured for 48 h. At day 7 or 8, the DC culture
supernatant was collected and frozen at 280uC. Then, mDCs
were harvested and stained with PE or FITC-conjugated
antibodies against CD11c, CD80, CD83, CD86, CD14, and
HLA-DR and their appropriate isotype-matched regents (BD
Pharmingen, USA). Cell surface expression was assayed by flow
cytometry (BD FACSCalibur, San Jose, CA), and Cellquest was
used to analyze the magnitude of surface molecule expression
on the mDCs. IL-12 and IL-10 levels were determined by
enzyme-linked immunosorbent assay (ELISA) (Bender MedSys-
tems, Vienna, Austria) according to manufacturer’s instructions.
Induction of Cellular Immune Response and IFN-c/GrB
ELISPOT Assay
mDCs were harvested and incubated with the DNA crosslinker
mitomycin C (30 mg/mL, Roche, Shanghai) to inhibit DC
proliferation and cytokine production for 40 min at 37uCi n5 %
CO2. mDCs were then washed 4 times with PBS and pulsed with
selected single peptide or multiple-epitope peptide mixtures for 2 h
at at 37uCi n5 %C O 2 in 96-well round plates. The autologous
cryopreserved PBMCs were used as the source of responder T
lymphocytes in the stimulation experiments. The autologous
responder T cells (2610
5/well) were cocultured with mDCs
loaded with single peptide or multiple-epitope peptide mixtures as
10:1 ratio for 72 h. Each peptide was added at a final
concentration of 10 mg/mL. The next day, AF-recombinant
human IL-2 (30 U/mL) (Peprotech, Rocky Hill, NJ, USA) was
added to the co-culture system. Single peptide or multiple-epitope
peptide mixtures were added into triplicate wells. T cell responder
cells were harvested and transferred to the pre-coated IFN-c or
Granzyme B (GrB) ELISPOT plates (BD Pharmingen, San Diego,
CA). The corresponding single peptide or multiple-epitope peptide
mixtures were added again to the ELISPOT wells and incubated
for 20 h at 37uCi n5 %C O 2. The ELISPOT plates were
developed as described above.
Cytokine Detection in Co-culture Supernatant
On day 4, the supernatant from DC co-culture with autologous
responder T lymphocytes was collected and fast frozen at 280uC
before the responder T cells were transferred to the ELISPOT
plates. The frozen supernatants were subsequently thawed, and
IL-2, IFN-c, IL-4, and IL-10(Human Th1/Th2 11plex FlowCy-
tomix Multiplex, Bender MedSystems/eBioscience, Vienna, Aus-
tria) were detected by flow cytometry at the same time according
to the manufacturer’s instructions and quantified using FlowCy-
tomix Pro 2.4 Software (eBioscience, USA).
Statistical Analysis
The continuous variables were expressed as mean6SEM. The
student’s t-test and one-way ANOWA were used to assess the
statistical difference between the different stimulatory groups. The
Table 1. Demographic characteristics of the subjects.
State No Gender Age (yr) HCV
# HCV RNA? ALT
* Co-existing disease
self-limited infection 1 F 45 15.15 negative 12 no
2 M 59 8.71 negative 15 no
3 M 60 5.83 negative 18 fatty liver
4 M 58 6.46 negative 12 fatty liver
5 F 43 6.17 negative 13 no
chronic infection 6 F 45 14.76 4.91E+06 18 no
7 M 50 15.19 4.88E+06 20 no
8 M 39 12.75 1.31E+07 44 alcohol
9 F 41 12.45 9.74E+05 26 no
10 M 47 14.65 2.02E+04 134 no
11 M 50 11.29 1.26E+07 31 fatty liver
Note:
#HCV Abs detected by ELISA (S/Co, Abbott).
Virus loads were quantified through quantitative real-time Taqman PCR (IU/mL, Roche).
*ALT (IU/mL);
‘‘no’’ means no combined diseases.
doi:10.1371/journal.pone.0038390.t001
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USA). A value of P,0.05 was considered significant.
Results
Seven Novel HLA-A2 Restricted HCV-specific CTL
Epitopes were Identified by Bioinformatics Screening and
Functioned to Induce IFN-c Production from PBMCs
To identify previously unknown HLA-A2-restricted epitopes in
HCV that are likely to prime CD8
+ T cells when presented by
DCs, a bioinformatics approach was used to identify suitable
candidates. Based on bioinformatics analysis using the criteria set
forth in the Materials and Methods, 21 HCV HLA-A2-restricted
epitopes were identified as candidates for CTL recognition; they
were identified by having higher scores than the threshold, which
we set at 0.36. Then we synthesized these 21 peptides and
functionally tested them by choosing which peptides could induce
peptide-specific IFN-c secretion from CTLs in PBMCs harvested
from both self-limited and chronic HCV subjects by IFN-c
ELISPOT assay. Using this assay, 7 functional peptides were
selected for their simulation ability (Figure 1 and Table 2)
according to our positive criteria in the materials and methods section.
These seven peptides were found to be located in all HCV regions.
Comparing the PBMC response to each peptide between the
self-limited and chronic HCV infection, we observed some
differences in stimulation capability. Only 2 of the 7 peptides
had the strongest stimulating capability in the self-limited HCV
infection PBMCs alone according to our criteria; these peptides
originated from the E2 (607–615) and NS2 (838–846) region. Five
peptides had a strong stimulating ability in both self-limited and
chronic HCV patient PBMCs. However, the peptide-induced
stimulation in the self-limited HCV infection was stronger than in
the chronic HCV infection. These 5 peptides corresponded to the
following HCV proteins: E2 (716–724), NS2 (834–842), NS3
(1411–1419), NS4a (1700–1708), and NS5b (2942–2950). We
subsequently used these selected peptides in the following
experiments to study the stimulation capability of DCs between
the self-limited and chronic HCV infections.
Taken together, we identified 7 novel HCV epitope peptides
that stimulated IFN-c secretion by bioinformatics screening and
subsequent functional studies in PBMCs from patient samples. In
addition to these novel HCV peptides, our screen also identified
nine previously reported HLA-A2-restricted HCV-specific CTL
epitopes by text mining; of these, four peptides were selected as
positive according to our criteria for stimulating IFN-c production
by ELISPOT assay. The detailed information about all peptides
identified in this study is listed in Table 2.
Activation Expression Markers and Cytokine Production
from Monocyte-derived DCs Induced to Mature in vitro
were not different between Self-limited and Chronic HCV
Infected Subjects
In order to obtain mature DCs from self-limited and chronic
HCV infected subjects to test the CTL-stimulation capacity of
the novel peptides we identified, we harvested CD14
+ mono-
cytes from PBMCs and induced them to differentiate and
develop into mDCs using the cytokine cocktail regimen detailed
in the Materials and Methods section. To determine whether
mDCs were produced, and to test whether there were any
differences in activation status between the mDCs derived from
self-limited or chronic HCV infected subjects, we first assessed
the activation status by measuring activation marker expression
by flow cytometry on day 8 of maturation. We found high
levels of mDC-specific markers CD80, CD86, CD83, CD11c,
and HLA-DR on all DCs; additionally, CD14 expression was
Figure 1. IFN-c SFCs of all predicted epitope peptides in study subjects. The data was expressed as mean6SEM and IFN-c SFCs per epitope
peptide, with the SFCs values from the negative control subtracted. The data from 5 self-limited and 6 chronic HCV infection subjects was included.
Triplicate wells of every peptide in the same experiments were used. A. IFN-c SFCs from the predicted peptides in self-limited HCV infection. B. IFN-c
SFCs from the predicted peptides in chronic HCV infection. ‘‘
w’’ stands for positive epitope peptide, which had the strongest stimulatory function of
IFN-c secretion in self-limited HCV infection and defined by .25 SFCs/2610
5 PBMCs after subtracting the negative control SFCs value.
doi:10.1371/journal.pone.0038390.g001
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these cells differentiated from the harvested CD14
+ monocytes
into mDCs (Figure S1). Comparing the DCs, there was no
difference in the mDC phenotype between DCs derived from
self-limited and chronic HCV infection subjects (P.0.05). This
result was consistent with some previous reports [27,31]. In
addition, we investigated the cytokine profile produced by the
mDCs since the Th1-skewing cytokine IL-12 is associated with
promoting CTL function. We found that the mDCs had higher
levels of IL-12 than IL-10 (a cytokine associated with Th2-
skewing). However, there was no significant difference between
the mDCs derived from the self-limited HCV infection and
chronic hepatitis C infection (data not shown). These data
indicated that the mDCs derived from self-limited HCV
infection and chronic hepatitis C infection are functionally
similar, and that mDCs could induce a Th1 immune response
during T cell priming.
Mature DCs Pulsed with Multiple Epitope Peptide
Mixtures were Able to Prime T Cell Responses
To evaluate the stimulation capability of selected peptides when
presented by the mDCs, we tested stimulation by measuring IFN-c
production from responding T cells on a per cell basis by
ELISPOT analysis. We first combined several peptides in different
combinations, including 6 peptides identified earlier in the study
and 3 previously reported peptides, to induce a strong and broad
T cell response. Fourteen unique epitope peptide pools were
created (Table S1); the peptides derived from both the structural
and non-structural regions in HCV to prime T cells against diverse
HCV targets. Confirming that PBMCs pulsed with these 14
peptide pools skewed toward Th1 rather than Th2 T cell
differentiation, each pool induced more Th1 cytokine IFN-c
production than the Th2 cytokine IL-4 (data not shown).
We found that DCs pulsed with either single or multiple-epitope
peptide pools could induce significantly more IFN-c SFCs in both
self-limited HCV infection and chronic HCV infection than the
HLA-A2-restricted CTL HBV envelope control and no peptide
control(Figure2A–B).AndthenumberofIFN-cSFCswasespecially
evident in chronic HCV infection-derived mDCs pulsed with the
single peptides or the multiple-epitope peptide combinations
(Figure2).Inaddition,wefoundthatseveralmultiple-epitopepeptide
combinationscouldsignificantlyinduceIFN-cSFCsinchronicHCV
infection compared to self-limited HCV infection(P,0.05,
Figure 2B).This result showed that the immunodominant epitopes
ofmultiple-epitopepeptidemixturescouldstimulatesignificantlevels
ofIFN-cproductionfromeffectorTcellsandsuggeststhattheycould
exert aprotective immune response.
Mature DCs Pulsed with Multiple Epitope-peptide
Mixtures Induced Epitope-specific Cytotoxic
Responses from CTLs
The cytotoxic function of CTLs plays an important role in
eliminating the hepatitis C virus from the host. To detect
whether epitope-specific cytotoxic T cell responses were induced
by mDCs loaded with single peptide or multiple-epitope peptide
mixtures, we used GrB ELISPOT assay (similar to a
51Cr-
release assay) to monitor T cell-mediated cytotoxicity [32,33].
Interestingly, we found that single-peptide pulsed DCs could
significantly enhance the number of GrB SFCs in the self-
limited HCV infection samples compared to no peptide control,
but not in the chronic HCV infection samples (Figure 3A).
However, we found that multiple-epitope peptide mixtures
pulsed DCs not only increased the number of GrB SFCs in the
self-limited HCV infection samples, but also in chronic HCV
infection samples. Especially three multiple-epitope peptide
pools (mix2,mix6 and mix7) could induce the more number
of GrB SFCs in chronic HCV infection than in self-limited
HCV infection and there was a significant difference in mix6
(P,0.05) between self-limited infection and chronic HCV
infection (Figure 3B). We also observed that the epitope peptide
mixtures that induced the high number of GrB SFCs included
the same novel immunodominant epitope peptides, which were
NS2 (834–842) and NS4a (1700–1708). Importantly, this CTL
immune response was HCV-epitope specific, because HLA-A2
restricted CTL epitope from HBV didn’t induce appreciable
GrB SFCs (Figure 3A–B). Taken together, our results suggest
that multiple-epitope peptide mixtures of immunodominant
peptides that are presented on mDCs can induce a cytotoxic
Table 2. Hepatitis C virus CTL epitopes prediction and identification.
Epitopes Position Sequence The number of positive subjects
Self-limited(n) Chronic infection (n)
CTL-1
g E2 (607–615) CLVDYPYRL 2/5
* 0
CTL-2
g NS2 (838–846) FLARLIWWL 2/5 0
CTL-3
g E2 (716–724) WEYVLLLFL 2/5 3/6
CTL-4
g NS2 (834–842) YYKVFLARL 2/5 2/6
CTL-5
g NS3 (1411–1419) GLNAVAYYR 2/5 2/6
CTL-6
g NS4a (1700–1708) VLYEAFDEM 2/5 2/6
CTL-7
g NS5b (2942–2950) KYLFNWAVK 3/5 2/6
CTL-8
¤ E2 (723–731) FLLLADARV 2/5 0
CTL-9
¤ NS3 (1073–1081) CINGVCWTV 3/5 3/5
CTL-10
¤ NS3 (1585–1593) YLVAYQATV 1/5 0
CTL-11
¤ NS5b (2594–2962) ALYDVVTKL 3/5 3/5
Note:
g stands for novel predicted epitopes.
¤stands for past reported epitopes.
wmeans two positives in five subjects.
doi:10.1371/journal.pone.0038390.t002
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infection patient CTLs in an antigen-specific manner.
Th1-biased Immune Response was Induced through DCs
Pulsed with Immunodominant Epitope Peptides
The cytokine spectrums from the responder T cells co-
cultured with mDCs pulsed with single peptide or multi-epitope
peptide were detected from the supernatant harvested from the
same cells used for the cytotoxicity assay. While high levels of
both IFN-c and IL-4 were observed in self-limited HCV
infection (Figure 4B, 4C), and we confirmed high levels of IL-2
and IL-10 in chronic HCV infection (Figure 4A, 4D). There
was a significant difference between self-limited HCV infection
and chronic HCV infection subjects (Figure 4A–D). Overall, our
data collectively suggests that not only single peptides but also
multiple-epitope peptide mixtures could induce a Th1-biased
immune response, although a complicated cytokine spectrum
was detected in the study subjects. These results are meaningful
in light of the differences in protective immune response against
hepatitis C infection between the chronic HCV and self-limited
subjects.
Figure 2. The frequency of IFN-c-producing CTLs from PBMCs cocultured with mDC loaded with peptides. The data was expressed as
mean6SEM. The data from 5 subjects for every group was included. Triplicate wells of every peptide in the same experiment were used. The single
peptides include 4 previously reported epitope peptides (E2 (723–731), NS3 (1073–1081), NS3 (1585–1593), and NS5b (2594–2602)), 7 predicted
peptides and HLA-A2-restricted CTL HBV envelope epitope peptide (WLSLLVPFV) as an unrelated peptide control. The epitope peptide mixtures
(mix1,mix14) contains 2 to 6 single epitope peptides in each mixture. A. IFN-c SFCs induced by single peptide in self-limited and chronic HCV
infection. B. IFN-c SFCs induced by multiple epitope peptide mixtures in self-limited and chronic HCV infection; *P,0.05.
doi:10.1371/journal.pone.0038390.g002
Figure 3. The frequency of GrB-producing CTLs from PBMCs cocultured with DC pulsed with epitope peptides. The data was
expressed as mean6SEM. The data from 5 subjects from every group was included. Triplicate wells from every peptide in the same experiment were
used. The single peptides include 4 previously reported epitope peptides (E2 (723–731), NS3 (1073–1081), NS3 (1585–1593), and NS5b (2594–2602)),
7 predicted peptides and HLA-A2 restricted CTL HBV envelope epitope peptide (WLSLLVPFV) as an unrelated peptide control. The epitope peptide
mixture (mix1,mix14) contains 2 to 6 single epitopes in each mixture. A. GrB SFCs induced by single peptide in self-limited and chronic HCV
infection. B. GrB SFCs induced by multiple epitope peptide mixtures in self-limited and chronic HCV infection; *P,0.05.
doi:10.1371/journal.pone.0038390.g003
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Although the mechanism of hepatitis C infection persistence is
complex, a strong, broad, and multiple-epitope T cell response is
associated with the termination of hepatitis C [11–13,34].
Therefore, the selection of immunodominant CTL epitopes may
play an important role when developing therapeutic strategies to
induce specific T cell responses, especially via epitope peptide-
pulsed DCs [20,22]. In this study, we screened the HCV proteome
and identified 7 novel HLA-A2-restricted HCV-specific CTL
epitopes in the Chinese population that demonstrated a strong
stimulating ability to induce epitope-specific IFN-c secretion,
especially in self-limited infections. Furthermore, mature DCs
pulsed with immunodominant epitopes could not only significantly
increase IFN-c secretion and GrB expression in T lymphocytes,
but also induce a Th1-biased cytokine immune response. Overall,
the results from this study indicate that these peptides could induce
a protective immune response and could therefore serve as
candidate peptides for the development of immunotherapy for
chronic HCV infection.
In recent years, many HCV immunodominant epitope peptides
have been identified in distinct regions throughout the HCV
proteome through different methods of identification [6,35–37].
However, of note, inappropriate epitope peptides might induce an
immune response that is not conducive to eliminate the HCV
infection [38]. Moreover, the synthesis of a peptide pool
containing all possible peptides would be costly. Therefore, we
sought out in this study to identify a few immunodominant
epitopes that have both high sensitivity and specificity by using a
bioinformatics approach using the online CTLpred software tool
followed by a functional IFN-c ELISPOT assay. Each of the 7
peptides identified by this process had a strong stimulating
capacity for IFN-c secretion and had relative conservation in
HCV genotype 1 and 2 (data not shown). This conservation in
other immunodominant epitope peptides has also been found in
subjects that recovered from HCV infection [39,40]. In addition to
revealing novel peptides by this screening method, we also selected
9 previously reported HLA-A2-restricted hepatitis C virus CTL
epitopes by using the text mining; these already established
peptides have been shown to induce a strong effect T cells
response in both self-limited HCV infection and chronic infection.
Surprisingly, only 4 peptides were finally identified as a positive
epitopes according to our criteria (Table 2). This phenomenon
indicates that immunodominant epitope peptides might relate to
the different patient populations. However, this needs further
investigation.
DCs have potent functions in the immune response, including
capturing and processing antigens, migrating to lymph nodes,
expressing co-stimulating molecules, and producing cytokines that
activate T lymphocytes. Although some studies have reported
impaired DC function in chronic hepatitis C infected patients [6–
8], we found in this study that there was no significant difference in
Figure 4. Cytokine concentrations in supernatants from T lymphocytes cocultured with DCs(pg/mL). The data was expressed as
mean6SEM, IL-2, IFN-c, IL-4, and IL-10 concentration in the supernatants from T lymphocytes in 4 self-limited HCV infections and 5 chronic HCV
subjects, cocultured with DCs loaded with single epitope peptide or multiple epitope peptide mixtures. Triplicate wells of every peptide in the same
experiment were used. The single peptides include 4 previously reported epitope peptides (E2 (723–731), NS3 (1073–1081), NS3 (1585–1593), and
NS5b (2594–2602)), 7 predicted peptides and HLA-A2 restricted CTL HBV envelope epitope peptide (WLSLLVPFV) as an unrelated-peptide control.
The epitope peptide mixture (mix1,mix14) contains 2 to 6 single epitopes in each mixture. A. IL-2 concentration. B. IFN-c concentration. C. IL-4
concentration. D. IL-10 concentration. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0038390.g004
DCs Pulsed with Epitopes Induced CTL Response
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38390co-stimulation molecule expression between chronic HCV infec-
tion and self-limited HCV subjects when we used a cytokine
cocktail and toll-like receptor ligand (PolyI:C) to promote
monocyte-derived DC maturation (Figure S1). Furthermore, the
mature DCs secreted higher levels of IL-12 than IL-10(data not
shown). This finding is consistent with past studies [31,41]. Taken
together, these characteristics suggested that mature DCs could
switch on a Th1-biased immune response and promote T cell
responses for immunotherapeutic purposes, as the inhibition of
DC function is associated with promoting CD8
+ T cell exhaustion
during chronic HCV infection [42].
Some evidence has indicated that multiple epitope peptides from
differentregionsoftheHCVgenomearenecessarytogeneratestrong
immunogenicityandstimulateawiderangeofepitope-specificCD8
+
Tcellresponses[43].Moreover,effectiveinductionoftheprotective
immuneresponsedependsontheappropriatecombinationofseveral
epitopepeptideswithinthesetofpeptidestouseforimmunotherapy
[44]. We therefore selected 6 novel peptides identified in this study
and3previouslyreportedHLA-A2-restrictedhepatitisCvirusCTL
epitopes tocomprisethe multiple-epitope peptide mixtures, asthese
peptides had a stronger stimulatory function as compared to the
others we functionally tested. Before mDCs pulsed with these
multiple-epitope peptide mixtures, we found that these epitope
peptide mixtures could induce more IFN-c production than IL-4
fromPBMCsharvestedfromchronicHCVinfectedsubjects(datanot
shown). Then we observed that mDCs pulsed with single peptide or
multiple-epitope peptide mixtures could induce significantly more
multi-epitope specific T cell responses than the controls, although
different antigen-recognition profiles were detected from different
subjects.ThesepulsedmDCsmainlyinducedhighnumberofIFN-c
secretion in self-limited HCV infection and chronic HCV infection,
especially multiple-epitope peptide mixtures in chronic HCV
infection (Figure 2B). However, as we expected, we found that only
multiple-epitopepeptidemixtures,notsingleepitopes,couldincrease
highernumberofGrBsecretionofCD8
+TcellsinchronichepatitisC
infectionthaninself-limitedHCVinfection(Figure3).Theseresults
demonstrate that multiple epitope peptide mixtures can induce a
broadTcellresponseandtheseTcellresponsemightcomefromthe
clone expansionof memoryT cells [6,11].
Previous work found that peptides from non-structural proteins
were able to stimulate CTL responses and that multiple epitope
peptide sequences were recognized by T cells within these non-
structural regions [45]. We further investigated whether our multi-
epitope peptide mixtures contain these same peptides; indeed, we
found that some of the peptides we identified were distributed in
non-structural protein regions of HCV. They were NS2 (834–
842), NS4a (1700–1708), and NS5b (2942–2950). However, we
also investigated multi-epitope peptide mixtures that contain more
than 5 peptides and found that they were not able to significantly
increase IFN-c or GrB secretion in the study subjects. This
suggests that just having more peptides in an epitope peptide
mixture may not necessarily translate into a better epitope peptide
mixture in terms of functional capacity to induce T cell effect
function. The mechanism behind what constitutes an appropriate
and effective stimulatory epitope peptide mixture will be explored
in future studies.
In addition to the cytotoxic role that CD8
+ T lymphocytes play
in the adaptive immune response during pathogen infection, they
also simultaneously secrete some cytokines, such as IL-2, IFN-c,
and TNF-a. These cytokines play a crucial role in eliminating
foreign pathogens [10,34,46]. In this study, we found that single
peptide or multiple-epitope peptide mixtures could induce the
production of high levels of Th1-biased immune response
cytokines (Figure 4A–D), although a different cytokine spectrum
was found when comparing self-limited HCV infection to chronic
HCV infection. In contrast, many studies have shown that a Th2-
biased cytokine immune response is present in persistent/chronic
HCV infection [47–49]. Although PBMCs stimulated by mDC
pulsed with 9-mer peptides, it is worth noting that cytokines might
also be secreted by CD4
+T cells, because cross-reactivity T cells
exist during the chronic infection. The mechanism needs to be
investigated in the future. Within our data, the cytokine profile we
found was at least consistent with the IFN-c and GrB SFCs results,
for example, there were high levels of IFN-c in coculture
supernatants and low IFN-c SFCs in the self-limited HCV
infection; However, this was converse in chronic HCV
infection(Figure 2 and Figure 4B). This indicated that the memory
T cells in self-limited HCV infection subjects can quickly clonal
expansion when faced with hepatitis C virus antigen again.
However, as persisting HCV infection or anergy of T cells,
inducing of the immune response in chronic HCV infection was
slow. These results further suggest that DCs pulsed with novel
multiple-epitope peptide mixtures can induce a wide range of
multi-epitope–specific T lymphocyte responses.
As described above, we identified 7 novel HLA-A2-restricted
HCV-specific CTL epitope peptides, and these peptides can
significantly increase the epitope-specific T cell response in self-
limited and chronic HCV infection subjects. But the number of
study subjects in this study is small; to confirm and extend these
results, we need to enlarge the study population in future studies.
Furthermore, this study only focused on the highly prevalent
HLA-A2-restricted epitopes in the population. However, other
HLA-I/II alleles have also been shown to be associated with
spontaneous clearance of hepatitis C infection [40,50,51], and
these would be interesting to study in the future as well.
Additionally, the detailed mechanism behind the different cytokine
spectrum observed in different subjects needs to be examined
closely in future studies. Overall, As DCs are characterized by
potent immunostimulatory properties in activating and attracting
T cells. And based on previous research in HIV infection and in
tumor immunotherapy, DCs pulsed with immunodominant
epitope peptides as an alternative strategy would be more efficient,
safer, and more feasible for hepatitis C immunotherapy than
currently available treatments [18,19,20,23,52], especially in
refractory hepatitis C virus.
In conclusion, we screened and identified seven novel HLA-A2
restricted hepatitis C virus specific CTL epitope peptides through
predictive screening by bioinformatics and functional testing by
IFN-c ELISPOT. We also found that DCs pulsed with multiple-
epitope peptide mixtures could increase the IFN-c and GrB
secretion of HCV-epitope-specific T cells above that of the
unrelated peptide and negative control. Moreover, the stimulation
induced by these peptides could induce a Th1-biased T cell
immune response, suggesting that these peptides could induce
epitope-specific T cells against HCV infection. Therefore, this
study not only reveals a promising immunodominant epitope
peptide candidate for designing effective therapeutic vaccines, but
also provides evidence that DC-based immunotherapy could work
to help eliminate HCV virus from chronic HCV-infected subjects.
Supporting Information
Figure S1 Surface molecules of monocyte-derived ma-
ture DC (%). The data was expressed as mean6SEM; data from
3 chronic HCV infection and 3 self-limited HCV infection subjects
was included. ‘‘ns’’ means no significance between self-limited
HCV infection and chronic HCV infection.
(TIF)
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